1. Home
  2. QNCX vs CTMX Comparison

QNCX vs CTMX Comparison

Compare QNCX & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Quince Therapeutics Inc.

QNCX

Quince Therapeutics Inc.

HOLD

Current Price

$3.56

Market Cap

139.2M

Sector

Health Care

ML Signal

HOLD

Logo CytomX Therapeutics Inc.

CTMX

CytomX Therapeutics Inc.

HOLD

Current Price

$4.39

Market Cap

596.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
QNCX
CTMX
Founded
2012
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
139.2M
596.2M
IPO Year
2019
2015

Fundamental Metrics

Financial Performance
Metric
QNCX
CTMX
Price
$3.56
$4.39
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
6
Target Price
$8.00
$6.50
AVG Volume (30 Days)
1.1M
2.9M
Earning Date
11-12-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
50.22
EPS
N/A
0.24
Revenue
N/A
$113,631,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$18.37
Revenue Growth
N/A
N/A
52 Week Low
$0.72
$0.40
52 Week High
$4.55
$4.62

Technical Indicators

Market Signals
Indicator
QNCX
CTMX
Relative Strength Index (RSI) 55.80 61.95
Support Level $3.44 $3.86
Resistance Level $3.80 $4.37
Average True Range (ATR) 0.34 0.26
MACD -0.10 0.02
Stochastic Oscillator 17.77 90.71

Price Performance

Historical Comparison
QNCX
CTMX

About QNCX Quince Therapeutics Inc.

Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.

About CTMX CytomX Therapeutics Inc.

CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

Share on Social Networks: